Detalhe da pesquisa
1.
Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms.
Leukemia
; 38(3): 502-512, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38114624
2.
Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen.
Curr Oncol
; 28(1): 128-137, 2020 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33704181
3.
Clinical Utility of Next-generation Sequencing in the Management of Myeloproliferative Neoplasms: A Single-Center Experience.
Hemasphere
; 2(3): e44, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31723772
4.
The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes.
Blood Adv
; 2(20): 2658-2671, 2018 10 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-30327374
5.
Clinical and molecular correlates of JAK-inhibitor therapy failure in myelofibrosis: long-term data from a molecularly annotated cohort.
Leukemia
; 36(6): 1689-1692, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35347238
6.
Azacitidine and venetoclax for the treatment of accelerated and blast phase myeloproliferative neoplasms and chronic myelomonocytic leukemia: a case series.
Leuk Lymphoma
; 62(6): 1525-1527, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33448888
7.
Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML.
Blood Adv
; 3(15): 2307-2311, 2019 08 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31371380